1,322
Views
4
CrossRef citations to date
0
Altmetric
Research Paper

Remarkable response with pembrolizumab plus albumin-bound paclitaxel in 2 cases of HER2-positive metastatic breast cancer who have failed to multi-anti-HER2 targeted therapy

, , , , , & show all
Pages 292-295 | Received 15 Aug 2017, Accepted 05 Dec 2017, Published online: 18 Jan 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Yadollah Omidi, Maha Mobasher, Ana M. Castejon & Morteza Mahmoudi. (2022) Recent advances in nanoscale targeted therapy of HER2-positive breast cancer. Journal of Drug Targeting 30:7, pages 687-708.
Read now

Articles from other publishers (3)

Shujie Li, Ying Wang, Xiaoran Wang, Jintang Feng, Dong-Sheng Guo, Zhaowei Meng, Yang Liu, Shao-Kai Sun & Zhanzhan Zhang. (2023) Macrocyclic-Albumin Conjugates for Precise Delivery of Radionuclides and Anticancer Drugs to Tumors. ACS Nano 17:22, pages 22399-22409.
Crossref
Na Qu, Chunyan Wang, Yiming Meng & Yuhua Gao. (2023) Superior Anticancer Potential of Nano-Paclitaxel Combined Bevacizumab Treatment in Ovarian Cancer. Current Pharmaceutical Biotechnology 24:9, pages 1204-1212.
Crossref
Shengwen Calvin Li & Mustafa H Kabeer. (2018) Spatiotemporal switching signals for cancer stem cell activation in pediatric origins of adulthood cancer: Towards a watch-and-wait lifetime strategy for cancer treatment. World Journal of Stem Cells 10:2, pages 15-22.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.